Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2021 | Story Leonie Bolleurs | Photo Supplied
With her talk on ‘Breaking the walls of darkness’, Emmie Chiyindiko came in second out of the 74 pitches presented at the recent Falling Walls Science Summit.

“I need you to take a moment and imagine trying to do everything that you do every day … without reliable energy. Or I’ll ask you this … How far would you walk to charge your phone if you didn’t have electricity? Would you walk for hours? Kilometres?”

“Well, that’s what millions of people in sub-Saharan Africa do daily to charge their phones. One billion people globally don’t have access to electricity in their homes and in sub-Saharan Africa, more than half of the population remains in the dark.”

This was the introduction to Emmie Chiyindiko’s talk at the recent Falling Walls Science Summit earlier this month. Emmie, who is a PhD student in Chemistry at the University of the Free State (UFS), came in second out of the 74 pitches presented with her talk on ‘Breaking the walls of darkness’ in the ‘Breakthrough of the year in the emerging talents category’.

Falling Walls Lab is a world-class pitching competition, networking forum, and steppingstone that brings together a diverse and interdisciplinary pool of students, researchers, and early-career professionals by providing a stage for breakthrough ideas, both globally and locally. 

Emmie, who sees getting out of bed every morning as just another opportunity to “be the exceptional young black female scientist that I am”, won the local Falling Walls Lab in Cape Town in October, which resulted in her going through to the finals in Berlin. She plans to host the Falling Walls Lab in Zimbabwe, her homeland, next year. 

This innovator and science communicator, whose work has been covered in Forbes Science, News24, and the Sunday Times, among others, refers to her obtaining second place on the international stage for her research as “a tremendous achievement and a new height in my science communication career. That level of recognition from the world leaders in science, technology, and science engagement cannot be overstated”.

Ending energy poverty

She believes Sustainable Development Goal 7 – leaving no one behind and eradicating global poverty – must be preceded by intentional efforts to end energy poverty. “My research on dye-sensitised solar cells (DSSC) with special metal complexes is among the most interesting alternatives to conventional solar cells.”

Emmie explains: “The design of the cells is inspired by photosynthesis – that good old process plants use to transform sunlight into energy via chlorophyll. Instead of a leaf, the cells start with a porous, transparent film of eco-friendly titanium dioxide nanoparticles. The film is also coated with a range of different dyes that absorb scattered sunlight and fluorescent light. When sunlight hits, it excites the electrons in the dye, creating an endless supply of energy. 

The bright side of this research is that there are several benefits to this invention. It produces energy that is cheap, reliable, and relatively simple and inexpensive to produce. Emmie adds: “These next-generation cells also work impeccably in low-light and non-direct sunlight conditions, providing all-year-round energy with no disruptions. DSSC is also three times cheaper than conventional cells and produces 40% more energy.”

Improving livelihoods 

She continues: “It does not degrade in sunlight over time as do other thin-film cells, making the cells last longer, and requiring less frequent replacement. DSSCs are also mechanically strong, because they are made of lightweight materials and do not require special protection from rain or abrasive objects.”

Emmie has proven that solutions to our current energy situation are available. “We are on the cusp of an energy revolution, and we must act now. Solutions are available, and if we do not seize them during a time of crisis, when will we?”

She believes that creating technology like this can end the energy crisis and improve livelihoods. “Billions of people simply lack enough energy to build a better life. Affordable, abundant, and reliable energy can go a long way to store food, power life-saving medical equipment, and run trains and factories. It can help communities to grow and prosper and to access opportunity and dignity. Societies where people have access to energy have lower childhood mortality, a higher life expectancy, they eat better and drink cleaner water, and have a better literacy rate.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept